AIM:To explore the circulating plasma miRNA-21 potential as early detection biomarker by comparing early-stage breast cancer (BG) and healthy control (HG) in Indonesian population. MATERIALS AND METHODS:The enlisted patients were twenty-six adult female early-stage breast cancer patients (stage 1A, 1B, 2A and 2B) of Airlangga University Hospital from August until October 2019. Sixteen volunteers were recruited as matched healthy subjects. MiRNA-21 expression was quantified by plasma qRT-PCR. Data analysis performed using IBM SPSS Statistics v.24. MiRNA-21 cut-off, sensitivity, and specificity were analyzed using receiver operating characteristic (ROC) curve. RESULTS:The subject includes 26 BG and 16 HG subjects. The miRNA-21 expression in BG group was 3.933 (1.181-11.794) and 0.905 (0.164-4.532) in HG group (4.34 folds; p=0.001), with 1.66 cut-off (92.3% sensitivity; 81.2% specificity). MiRNA-21 expression separated analysis in HG showed a 0.578 times lower expression in menopause subjects [0.651 (0.164-0.414)] compared to pre-menopause [(1.123 (0.758-4.532); p=0.031]. Yet, in BG group 1.729 times higher miRNA-21 expression was observed in menopause subjects (6.021±3.583) compared to pre-menopause subjects (3.500±1.517;p=0.022). CONCLUSION:Circulating miRNA-21 expression is a potential biomarker for early detection of breast cancer and might act as a breast cancer risk predictor. Key words: Biomarkers, breast neoplasms, diagnosis, human plasma, miRNA-21.
Turk J Med Sci (Turkish journal of medical sciences)
Cited: 0 times